333 related articles for article (PubMed ID: 21742774)
1. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.
Righi E; Kashiwagi S; Yuan J; Santosuosso M; Leblanc P; Ingraham R; Forbes B; Edelblute B; Collette B; Xing D; Kowalski M; Mingari MC; Vianello F; Birrer M; Orsulic S; Dranoff G; Poznansky MC
Cancer Res; 2011 Aug; 71(16):5522-5534. PubMed ID: 21742774
[TBL] [Abstract][Full Text] [Related]
2. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
4. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
[TBL] [Abstract][Full Text] [Related]
5. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
6. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
Jiang YP; Wu XH; Xing HY; DU XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
[TBL] [Abstract][Full Text] [Related]
7. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
[TBL] [Abstract][Full Text] [Related]
9. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
11. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
12. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
Hall JM; Korach KS
Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
[TBL] [Abstract][Full Text] [Related]
13. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton CJ; Wilson JL; Scott K; Stamp G; Wilbanks GD; Fricker S; Bridger G; Balkwill FR
Cancer Res; 2002 Oct; 62(20):5930-8. PubMed ID: 12384559
[TBL] [Abstract][Full Text] [Related]
14. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
15. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
[TBL] [Abstract][Full Text] [Related]
16. CXCL12-CXCR4 Axis Promotes Proliferation, Migration, Invasion, and Metastasis of Ovarian Cancer.
Guo Q; Gao BL; Zhang XJ; Liu GC; Xu F; Fan QY; Zhang SJ; Yang B; Wu XH
Oncol Res; 2014; 22(5-6):247-58. PubMed ID: 26629936
[TBL] [Abstract][Full Text] [Related]
17. Role of CXCL12 in metastasis of human ovarian cancer.
Jiang YP; Wu XH; Xing HY; DU XY
Chin Med J (Engl); 2007 Jul; 120(14):1251-5. PubMed ID: 17697577
[TBL] [Abstract][Full Text] [Related]
18. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
19. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
20. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
